NCT00241228

Brief Summary

Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
139

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2005

Longer than P75 for not_applicable

Geographic Reach
3 countries

16 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

October 17, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 18, 2005

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
Last Updated

October 13, 2010

Status Verified

October 1, 2010

Enrollment Period

5 years

First QC Date

October 17, 2005

Last Update Submit

October 12, 2010

Conditions

Keywords

Shock, SepticRenal Failure, AcuteVenovenous HemofiltrationRandomized Controlled TrialMulticenter StudyMortality

Outcome Measures

Primary Outcomes (1)

  • all-cause mortality.

    28-day

Secondary Outcomes (8)

  • Haemodynamic parameters and volume loading

    Every 12 hours during 96 hours after inclusion

  • Doses and duration of catecholamine infusions

    Every 12 hours during 96 hours after inclusion

  • Organ failures

    During 96 hours after inclusion

  • Duration of mechanical ventilation

    Total during the stay in intensive care

  • Duration of renal replacement therapy

    Total during the stay in Intensive Care Unity (ICU)

  • +3 more secondary outcomes

Study Arms (2)

High Volume

EXPERIMENTAL

ultra filtration : High volume : 70 ml/kg/h

Device: Venovenous haemofiltration (renal replacement therapy)

Medium Volume

ACTIVE COMPARATOR

Ultra filtration : conventional volume : 35 ml/kg/h

Device: Venovenous haemofiltration (renal replacement therapy)

Interventions

High Volume ultra filtration (70 ml/kg/h)

High Volume

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • septic shock (Bone criteria) for less than 24 hours
  • RIFLE criteria : injury or worse
  • age over 18 years
  • written informed consent by next of kin.

You may not qualify if:

  • cirrhosis
  • age over 80 years
  • life expectancy less than 3 months or metastatic cancer
  • for women : pregnancy and breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

Cliniques de l'Europe

Brussels, Belgium

Location

Astrid Queen Military Hospital

Bruxelles (Neder Over Hembeek), Belgium

Location

TIVOLI Hospital

La Louvière, Belgium

Location

University Hospital

Liège, Belgium

Location

St-Pierre Para-University Hospital

Ottignies-Louvain-la-Neuve, Belgium

Location

Hospital

Agen, 47923, France

Location

Clinic Bordeaux Nord

Bordeaux, 33077, France

Location

University Hospital

Brest, 29200, France

Location

University Hospital

Grenoble, 38600, France

Location

Hospital R Boulin - Libourne

Libourne, 33505, France

Location

University Hospital

Lyon, 69317, France

Location

Aphp - Hegp

Paris, 75908, France

Location

Service d'Anesthésie-Réanimation II, Groupe Hospitalier Sud, CHU de Bordeaux

Pessac, 33604, France

Location

Hospital

Tourcoing, 59209, France

Location

Hospital

Delf, Netherlands

Location

Hospital

Heerlen, Netherlands

Location

Related Publications (2)

  • Medica D, Quercia AD, Marengo M, Fanelli V, Castellano G, Fabbrini P, Migliori M, Merlotti G, Camussi G, Joannes-Boyau O, Honore PM, Cantaluppi V. High-volume hemofiltration does not protect human kidney endothelial and tubular epithelial cells from septic plasma-induced injury. Sci Rep. 2024 Aug 7;14(1):18323. doi: 10.1038/s41598-024-69202-z.

  • Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL, Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Roze H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013 Sep;39(9):1535-46. doi: 10.1007/s00134-013-2967-z. Epub 2013 Jun 6.

MeSH Terms

Conditions

Shock, SepticAcute Kidney Injury

Interventions

Renal Replacement Therapy

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShockRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Olivier JOANNES-BOYAU, Dr

    University Hospital, Bordeaux, France

    PRINCIPAL INVESTIGATOR
  • Patrick HONORE, Dr

    Quuen Astrid Military Hospital, BRUXELLES - Belgium

    PRINCIPAL INVESTIGATOR
  • Paul Perez, Dr

    University Hospital, Bordeaux, France

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 17, 2005

First Posted

October 18, 2005

Study Start

October 1, 2005

Primary Completion

October 1, 2010

Study Completion

October 1, 2010

Last Updated

October 13, 2010

Record last verified: 2010-10

Locations